News | News By Subject | News by Disease News By Date | Search News

Lung cancer News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AstraZeneca PLC (AZN) Stock Hits 2017 High as Lung Cancer Med Reduces Death Risk in Phase III Study     5/15/2017
Catastrophic Year for Bay Area's OncoMed (OMED) Continues as Lead Drug Comes Crashing Down in Phase II Study     5/9/2017
Takeda (TKPYY)'s $5 Billion Bet on Ariad (ARIA) Pays Off With Accelerated Approval of Lung Cancer Med     5/1/2017
The FDA Calls Pfizer (PFE)’s Next-Generation Lung Cancer Drug a Breakthrough     4/28/2017
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed     4/27/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study     4/18/2017
How This Drug Candidate Could be a Winner in Gilead (GILD)'s Pipeline     3/23/2017
Heat Biologics (HTBX) Rockets as Lung Cancer Med Hits Mid-Stage Goals     3/22/2017
Genentech (RHHBY)'s $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire     2/8/2017
The 7 Worst Clinical Disasters of 2016     12/27/2016
Concordia (CXR.TO) Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index     12/19/2016
Bristol-Myers Squibb (BMY) Looks Over Its Shoulder as Opdivo Disappoints While Merck & Co. (MRK)'s Keytruda Shines in Lung Cancer Study     10/10/2016
Genentech (RHHBY)’s Lung Cancer Drug Alecensa Gets 2nd FDA Breakthrough Status     10/5/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle     9/23/2016
FDA Grants Priority Review and Breakthrough Tag for Merck & Co. (MRK)’s Keytruda     9/7/2016

News from Around the Web
How Did Bristol-Myers Squibb (BMY) Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss     6/5/2017
New Blood Test Could Treat Non-Small-Cell Lung Cancer Faster, The Journal of Molecular Diagnostics Reveals     4/19/2017
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug     2/17/2017
Liquid Biopsy For Lung Cancer Provides Rapid Results At Low Cost And No Trauma, Stanford University Study     1/6/2017
Czech Scientists Develop Human Lung Model To Aid Treatments, Brno University Of Technology Study     11/29/2016
Balance Of Power Shifts With Merck & Co. (MRK)'s Keytruda First-Line Therapy Approval In Lung Cancer     10/26/2016
Genentech (RHHBY)’s Tecentriq Wins Second Approval of the Year, This Time for Lung Cancer     10/19/2016
AI Beats Doctors At Visual Diagnosis, Observes Many Times More Lung Cancer Signals, Stanford University Study     8/19/2016
Transgenomic, Inc. (TBIO) Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer     7/25/2016
University of Louisville Teams Up With Company To Help Lung Cancer Diagnosis     6/15/2016
This Diet Ups Your Lung Cancer Even If You Don't Smoke, MD Anderson Cancer Center Study     3/9/2016
Biotech Startup Yihuo Bio To Produce New Device For Early Detection Of Lung Cancer     2/29/2016
Could A Lung Cancer Drug Work Better With Coke? Erasmus MC Study     2/16/2016
This Lung Cancer Drug May Not Be What It Seems, Chemists Say     1/4/2016
Study Suggests Indi's Xpresys Test Could Reduce Invasive Procedures In NSCLC Diagnosis     12/23/2015

Press Releases
Novartis AG (NVS) Combination Targeted Therapy Tafinlar + Mekinist Receives FDA Approval For BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)     6/23/2017
Novartis AG (NVS) Combination Targeted Therapy Tafinlar + Mekinist Receives FDA Approval For BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)     6/23/2017
FDA Approves Thermo Fisher Scientific (TMO)'s First Companion Diagnostic Test to Screen Multiple Non-Small Cell Lung Cancer Therapies     6/23/2017
GENFIT (ALGFT) Reaches A Critical Milestone Towards The Development Of A Non-Invasive In Vitro Diagnostic (IVD) Test For NASH     6/23/2017
Elekta Release: New Data From The Elekta Lung Research Group Support The Use Of Stereotactic Body Radiation Therapy In Elderly Patients With Early-Stage Lung Cancer     6/15/2017
Questions Rise As Incyte (INCY) Omits Response Rate Data From Several Patients Enrolled In IDO Lung Cancer Study     6/5/2017
ARMO BioSciences Announces Promising Response Rates And Survival Data In Patients With Advanced NSCLC And RCC From Phase I/Ib Trial For Immunotherapy AM0010 With Checkpoint Inhibitors     6/5/2017
CARsgen Therapeutics Presents Phase I Results Of CAR-GPC3 T HCC Trial At ASCO 2017 Annual Meeting     6/5/2017
Phase III Study Showed Genentech (RHHBY)’s Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer     6/5/2017
Peregrine (PPHM) Presents Preliminary Correlative Analysis Of PD-L1 Expression From SUNRISE Trial At ASCO 2017     6/5/2017
Incyte (INCY) Release: Combination Of Epacadostat Plus Keytruda (Pembrolizumab) Demonstrates Activity In Clinical Trial Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)     6/5/2017
Longer Term Follow-Up Data With Merck & Co. (MRK)’S KEYTRUDA (Pembrolizumab) In Combination With Pemetrexed And Carboplatin In First-Line Nonsquamous Metastatic Non-Small Cell Lung Cancer (NSCLC) To Be Presented At 2017 ASCO Annual Meeting     6/5/2017
Corvus Pharma Announces Interim Results Demonstrating Anti-Tumor Activity Of CPI-444 In Renal And Lung Cancer Patients Resistant Or Refractory To Prior PD-(L)1 Treatment     6/5/2017
OxOnc Announces That Co-Development Partner Has Received Approval In Japan And Taiwan For Crizotinib (Xalkori) As A First-Line Treatment For Patients With ROS1-Positive Non-Small Cell Lung Cancer     6/2/2017
Vaxon Biotech SA Announces Results Of Its Phase IIb Lung Cancer Trial Of Vx-001, A Therapeutic Vaccine Based On Optimized Cryptic Peptides     6/1/2017